Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
SeaWorld rescue
Stonehenge
Ariana Grande
NATO exercise
Obama Center
Border wall
Japan embarrassed
Winter storm
Food pantries
Super snow moon
Anadarko
Health News
Jan. 19, 2019 / 4:41 PM

FDA: Irbesartan lots recalled over likely carcinogen

By
Sommer Brokaw
Blood pressure manometer and medication. Photo by ronstik/Shutterstock

Jan. 19 (UPI) -- A drug company has recalled more irbesartan blood pressure medication after discovering a potential human carcinogen.

Prinston Pharmaceutical, doing business as Solco Healthcare, has voluntarily recalled of eight more lots of irbesartan blood pressure medication after detecting trace amounts of impurity in an active pharmaceutical ingredient, the Food and Drug Administration announced Friday.

The ingredient in question contains N-nitrosodiethylamine (NDEA), "a substance that occurs nationally in certain foods, drinking water, air pollution, and industrial processes" and has been classified by the International Agency for Research on Cancer as a probable human carcinogen.

NDEA was manufactured by a factory in China called Zhejiang Huahai Pharmaceuticals, which has been linked to several recalls of blood pressure drugs dating back to July.

RELATED Study: Soft drinks, exercise, hot temps increase risk for kidney disease

Lots of other blood pressure and heart medications such as valsartan, losartan, amlopidine and hydrochlorothiazide have also been recalled since July.

The FDA issued an import alert in September to block products made at the China plant from entering America and issued a warning letter in November about challenges including impurity control.

Hetero Labs, another factory in India, has also been linked to multiple recalls.

RELATED Heart healthy diet reduces diabetes risk, study says

Prinston will only be recalling lots of irbesartan-containing products that contain NDEA above the acceptable intake levels released by the FDA.

"Patients who are on Irbesartan should continue taking their medication, until their pharmacist provides a replacement, or their doctor prescribes a different medication that treats the same condition as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment," the FDA statement said.

RELATED Black teens see twice the junk food ads as white teens, study says
  • Topics
  • Food and Drug Administration
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Study: High-carb, low-protein diets may extend lifespan
Gender transition hormone therapy may increase cardiovascular risk
Number of push-ups men can do in a row may indicate heart health
Apple-, pear-shaped body determined by genetics, study says
Nuts may lower cardiovascular disease risk from type 2 diabetes

Photo Gallery

 
Palestinians celebrate Valentine's Day

Latest News

Morning exercise may lower blood pressure for older, obese people
Climate change: Winters of future will be colder -- and also warmer
Author Ron Stallworth: Racism in 'Black Klansman' resonates in Trump era
UPI Almanac for Wednesday, Feb. 20, 2019
Famous birthdays for Feb. 20: Rihanna, Ivana Trump
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy